Single-Cell Multiomics Enables Superior MRD Detection and Therapeutic Insight in Myeloid Malignancies

Sensitive detection of measurable residual disease (MRD) and therapy-resistant clones is critical in myeloid malignancies, yet standard bulk assays often miss rare subpopulations or misclassify benign clonal hematopoiesis. Single-cell multiomic profiling overcomes these limitations by simultaneously capturing genotype and phenotype. This approach offers superior sensitivity over conventional methods, accurately distinguishing leukemic from preleukemic cells while mapping co-mutant subclones and clonal hierarchies. These high-resolution insights improve relapse prediction, define biomarkers, and characterize resistance mechanisms. Consequently, single-cell multiomics establishes a unified framework that strengthens both clinical monitoring and precision therapeutic development.